In this week's episode we dive into how chronic inflammation connects kidney disease with cardiovascular risk. Learn how inflammation, typically the body’s healing response, can become a destructive force when it lingers, contributing to kidney damage and cardiovascular issues like high blood pressure and artery hardening. We’ll also explore why CKD patients are often underserved in cardiovascular treatment and how emerging research aims to bridge that gap. Join us to understand the vital role inflammation plays in these two essential systems and what’s being done to manage it. 

Share with a friend. Rate, Review, and Subscribe to MedEvidence Articles to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube

For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence podcast. www.MedEvidence.com

Thank you for listening!

References:

Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation, 143(11), 1157-1172. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686

Ridker, P. M., MacFadyen, J. G., Thuren, T., & Libby, P. (2020). Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. European heart journal, 41(23), 2153-2163. https://pubmed.ncbi.nlm.nih.gov/31504417/

Stenvinkel, P. (2006). Inflammation in end‐stage renal disease: The hidden enemy. Nephrology, 11(1), 36-41. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1440-1797.2006.00541.x

Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., ... & Newby, L. K. (2015). Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation, 131(12), 1123-1149. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000183

Vidt, D. G. (2006). Inflammation in renal disease. The American journal of cardiology, 97(2), 20-27. https://doi.org/10.1016/j.amjcard.2005.11.012

Vilaysane, A., Chun, J., Seamone, M. E., Wang, W., Chin, R., Hirota, S., ... & Muruve, D. A. (2010). The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. Journal of the American Society of Nephrology, 21(10), 1732-1744. https://pmc.ncbi.nlm.nih.gov/articles/PMC3013544/

Zoccali, C., & Mallamaci, F. (2023). Innate immunity system in patients with cardiovascular and kidney disease. Circulation research, 132(8), 915-932. https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.122.321749